Coherus BioSciences (CHRS) Scheduled to Post Quarterly Earnings on Thursday

Coherus BioSciences (NASDAQ:CHRS) is scheduled to be releasing its earnings data after the market closes on Thursday, May 9th. Analysts expect Coherus BioSciences to post earnings of ($0.05) per share for the quarter. Parties that wish to register for the company’s conference call can do so using this link.

Coherus BioSciences (NASDAQ:CHRS) last issued its quarterly earnings results on Wednesday, March 13th. The biotechnology company reported ($0.72) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.39). The business had revenue of $91.52 million during the quarter, compared to the consensus estimate of $105.30 million. On average, analysts expect Coherus BioSciences to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Coherus BioSciences Stock Performance

Shares of CHRS stock opened at $2.25 on Wednesday. Coherus BioSciences has a fifty-two week low of $1.43 and a fifty-two week high of $8.22. The firm has a market capitalization of $255.38 million, a PE ratio of -0.88 and a beta of 0.56. The stock’s 50-day simple moving average is $2.26 and its 200-day simple moving average is $2.39.

Wall Street Analyst Weigh In

A number of research firms have issued reports on CHRS. HC Wainwright reduced their price target on shares of Coherus BioSciences from $13.00 to $11.00 and set a “buy” rating for the company in a research report on Wednesday, March 20th. Robert W. Baird decreased their target price on shares of Coherus BioSciences from $11.00 to $9.00 and set an “outperform” rating for the company in a research report on Tuesday, January 23rd. Finally, Truist Financial cut their price target on Coherus BioSciences from $12.00 to $8.00 and set a “buy” rating on the stock in a research report on Tuesday, January 23rd. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $9.29.

About Coherus BioSciences

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.